BCR and B-cell chronic lymphocytic leukemia: Idelalisib, which targets PI3Kδ in the BCR pathway, only generates a partial response in CLL patients, though the concomitant inactivation of PI3Kβ reduces further downstream activation in patient-derived CLL cells [53].